1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 May 2024
Admin
News Article

Astrazeneca Gets into Partnership to Enhance Respiratory Care for Severe Asthma Patients

AstraZeneca and Vaayu Chest & Sleep Centre collaborate to enhance respiratory care for severe asthma patients

Overview

AstraZeneca Pharma has partnered with Vaayu Chest & Sleep Centre to elevate the standard of respiratory care for severe asthma patients in Bengaluru.

Asthma: a Prevalent Disease in India

Severe asthma poses a significant challenge as a prevalent non-communicable disease in India, contributing to premature morbidity and mortality.
Recent data indicates that approximately 22 lakhs of individuals in Karnataka are grappling with asthma, placing the state seventh in terms of asthmatic population in India.

COEs for Asthma care

The Centres of Excellence (COEs) for severe asthma, aligned with the Global Initiative for Asthma (GINA) guidelines, are designed to offer a systematic and uniform approach to managing patients with severe asthma.
Since the start of this year, AstraZeneca's Severe Asthma COEs have screened over 3000 patients nationwide, accurately assessing disease severity and providing tailored treatment through skilled healthcare professionals engaged in AstraZeneca's educational initiatives.
The company aims to establish 20 clinics across India by the end of 2024, anticipating to screen over 10,000 COE patients.

Words from AstraZeneca

Dr Anil Kukreja, vice president - medical affairs & regulatory, AstraZeneca India, said, “Our collaboration with Vaayu Center underscores our commitment to providing innovative solutions and improving patient outcomes. We are dedicated to filling this gap through our COE network, which not only monitors patients but also educates healthcare providers, offering comprehensive respiratory care solutions to enhance the quality of life for those with NCDs.”

Specialized Asthma Clinics: New hope

NCDs such as severe asthma can become a socio-economic burden for the patients, their families, and the healthcare system due to the various treatment costs involved.
As a result, effective disease management requires specialized care from a multidisciplinary team of healthcare professionals and caregivers.
The establishment of specialized asthma clinics represents a leap forward in technological advancements and holistic disease management.

Vaayu Chest and Sleep Specialists on World Asthma Day

Dr Ravindra Mehta, director and head and Dr. Sameer Bansal, Clinical Head at Vaayu Chest and Sleep Specialists said, “World Asthma Day 2024 has an interesting theme ""Asthma Education Empowers.""
It is crucial to understand that knowledge is power, and empowerment is therapy when it comes to managing this respiratory condition.
Asthma affects millions worldwide, and in India, its prevalence is significant, with Bengaluru infamously dubbed as “Asthma Capital of India”.
India accounts for 13.9% of global asthma burden, while contributing to 42% of global asthma related deaths.
However, with the right information and proactive measures, individuals can lead fulfilling lives despite this chronic illness.
Our aim at Vaayu in 2024 is knowledge, education and commitment to beat the asthma pandemic.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!